查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600935

玻糖醛酸酶市場：按類型、給藥途徑、應用和最終用途分類 - 2025-2030 年全球預測

Hyaluronidase Market by Type (Animal-Derived Hyaluronidase, Synthetic Hyaluronidase), Route of Administration (Injection Route, Subcutaneous Route), Application, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年玻糖醛酸酶市值為10.1億美元，預計2024年將達11.6億美元，複合年成長率為14.43%，預計2030年將達26.2億美元。

玻糖醛酸酶是指一組催化透明質酸分解的酶，主要用於增加組織滲透性，促進其他注射藥物的分散，並增強局部麻醉劑的效果。玻糖醛酸酶在眼科手術、真皮填充劑製備和腫瘤治療等醫療和美容手術中的重要作用強調了對透明質酸酶的需求。其應用涵蓋多個行業，包括製藥、化妝品和診斷等主要最終用途領域。市場洞察表明，對微創和非手術美容手術的需求不斷成長是玻糖醛酸酶市場的關鍵促進因素。此外，癌症盛行率的增加和腫瘤學的進步正在推動市場擴張，因為玻糖醛酸酶顯著增強了化療藥物的療效。最新的商機在於個人化醫療的成長趨勢以及利用玻糖醛酸酶促進藥物分散的新型遞送系統的開發。然而，市場成長受到高製造成本、潛在副作用和嚴格法律規範等挑戰的阻礙。此外，某些地區的意識低和缺乏訓練有素的專業人員也可能阻礙市場滲透。為了實現業務成長，有些領域需要技術創新和研究，例如開發重組玻糖醛酸酶產品、提高酵素穩定性以及在正在開發醫療基礎設施的開發中國家擴大應用。此外，探索玻糖醛酸酶與新配方和藥物傳輸技術的融合可能會提供競爭優勢。市場競爭非常激烈，許多參與者都致力於創新，這凸顯出需要進行嚴格的市場研究和策略夥伴關係，以利用新興趨勢並克服現有挑戰。

主要市場統計
基準年[2023] 10.1億美元
預測年份 [2024] 11.6億美元
預測年份 [2030] 26.2億美元
複合年成長率（%） 14.43%

市場動態：揭示快速發展的玻糖醛酸酶市場的關鍵市場洞察

供需的動態交互作用正在改變玻糖醛酸酶市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 消費者對化妝品和美容護理的偏好不斷增加
    • 擴大藥品生產和利用玻糖醛酸酶促進藥物吸收
    • 玻糖醛酸酶產品獲得監管部門的有利核准
  • 市場限制因素
    • 製造和配製玻糖醛酸酶解決方案的問題
  • 市場機會
    • 持續創新和臨床試驗以提高玻糖醛酸酶的功能和效率
    • 在眼科手術中使用玻糖醛酸酶的可能性以及提高玻糖醛酸酶認知的努力
  • 市場挑戰
    • 玻糖醛酸酶可能出現過敏反應和性能問題

波特五力：駕馭玻糖醛酸酶市場的策略工具

波特的五力框架是了解玻糖醛酸酶市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解玻糖醛酸酶市場的外部影響

外部宏觀環境因素在塑造玻糖醛酸酶市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解玻糖醛酸酶市場的競爭狀況

對玻糖醛酸酶市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣玻糖醛酸酶市場供應商績效評估

FPNV定位矩陣是評估玻糖醛酸酶市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了玻糖醛酸酶市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，玻糖醛酸酶市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 消費者對整容手術的興趣日益濃厚
      • 利用玻糖醛酸酶擴大藥物生產並促進藥物吸收
      • 玻糖醛酸酶產品的監管核准
    • 抑制因素
      • 與創建和配製玻糖醛酸酶解決方案相關的問題
    • 機會
      • 持續創新和臨床試驗以提高玻糖醛酸酶的功能和效率
      • 玻糖醛酸酶在眼科手術中的潛在用途以及提高玻糖醛酸酶認知的努力
    • 任務
      • 可能的玻糖醛酸酶酶過敏反應和性能問題
  • 市場區隔分析
    • 類型：生物技術和倫理考慮的不斷進步導致更多地採用合成玻糖醛酸酶
    • 給藥途徑：臨床實務中優選注射途徑，因為全身性作用發生得更快。
    • 應用：玻糖醛酸酶在美容手術和皮膚病治療的新多功能應用
    • 最終用途：擴大世界各地醫院和診所提供的服務和醫療程序
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章玻糖醛酸酶市場：依類型

  • 動物源性玻糖醛酸酶
  • 合成玻糖醛酸酶酶

第7章玻糖醛酸酶市場：依給藥途徑

  • 注射途徑
  • 皮下給藥

第8章玻糖醛酸酶市場：依應用分類

  • 化療
  • 皮膚科
  • 眼科
  • 整形外科

第9章玻糖醛酸酶市場：依最終用途

  • 門診手術中心
  • 醫院/診所

第10章美洲玻糖醛酸酶市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區玻糖醛酸酶市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲玻糖醛酸酶市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Creative Enzymes 介紹重組人類玻糖醛酸酶PH20
    • 強生公司針對 Darzalex Faspro 的 sBLA 申請
    • 癌症治療的突破：3 期研究證明皮下注射 Nivolumab 在腎細胞癌的非劣效性
    • 日本厚生勞動省核准VYVDURA 擴大了 gMG 患者的治療選擇
    • 核准將 HYQVIA 的用途擴大到 CIDP 維持治療
    • 中外製藥的Phesgo在日本上市，為 HER2 陽性癌症的治療帶來革命性進展
    • Acumen Pharmaceuticals 與 Halozyme 合作增強阿茲海默症的治療效果
    • Arteogen 的 Telgase 在 ADA 發生率為零的臨床試驗中顯示出可喜的結果
    • Arteogen 和 Sandoz 結成策略聯盟，共同開發皮下生物相似藥
  • 戰略分析和建議
    • 默克
    • 恩法斯特製藥有限公司
    • 庫柏外科有限公司
    • Halozyme 治療公司
    • 博士健康公司有限公司

公司名單

  • Alteogen Inc.
  • Amphastar Pharmaceuticals, Inc.
  • Argenx SE
  • Bausch Health Companies Inc.
  • BBI Solutions by Novo Holdings A/S
  • Bioindustria LIM spa
  • Cell Signaling Technology, Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • CooperSurgical, Inc.
  • Creative Enzymes
  • Ferro Pharma GmbH
  • FUJIFILM Holdings Corporation
  • Glentham Life Sciences Limited
  • GYNEMED GmbH & Co. KG by Hamilton Thorne Ltd.
  • Halozyme Therapeutics, Inc.
  • Innovative Research
  • Johnson & Johnson Services, Inc.
  • Kitazato Corporation
  • Kraeber & Co GmbH
  • Laboratorio Innoaesthetics, SLU
  • Merck KGaA
  • Sanofi
  • Shreya Life Sciences Pvt. Ltd
  • STEMCELL Technologies Canada Inc.
  • Sun Pharmaceutical Industries Limited
  • Sunways（India）Private Limited
  • Taj Pharmaceuticals Ltd.
  • Takeda Pharmaceutical Company Limited
  • Wockhardt Limited
  • Worthington Biochemical Corporation
Product Code: MRR-22146147668D

The Hyaluronidase Market was valued at USD 1.01 billion in 2023, expected to reach USD 1.16 billion in 2024, and is projected to grow at a CAGR of 14.43%, to USD 2.62 billion by 2030.

Hyaluronidase refers to a group of enzymes that catalyze the degradation of hyaluronic acid, predominantly used to increase tissue permeability, promote the dispersion of other injected drugs, and enhance the efficacy of local anesthetics. The necessity of hyaluronidase is underscored by its critical role in medical and aesthetic procedures, including ophthalmic surgeries, dermal filler adjustments, and oncology treatments. Its application spans across various industries, with key end-use sectors including pharmaceuticals, cosmetics, and diagnostics. The market insights reveal that the growing demand for minimally invasive and non-surgical aesthetic procedures is a significant driver for the Hyaluronidase market. Furthermore, the increasing prevalence of cancer and advancements in oncology are fostering the market expansion, as hyaluronidase significantly enhances the efficacy of chemotherapeutic agents. The latest opportunities lie in the rising trend of personalized medicine and the development of novel delivery systems that leverage hyaluronidase's ability to promote drug dispersion. However, market growth is challenged by factors such as high production costs, potential adverse reactions, and stringent regulatory frameworks. Limitations also include the lack of awareness and trained professionals in some regions, which may hinder market penetration. For business growth, areas ripe for innovation and research include the development of recombinant hyaluronidase products, improving enzyme stability, and expanding applications in developing countries where healthcare infrastructure is improving. Additionally, exploring the integration of hyaluronidase with new drug formulations and delivery technologies can present competitive advantages. The market is highly competitive with numerous players striving for innovation, thus emphasizing the necessity for rigorous market research and strategic partnerships to capitalize on emerging trends and overcome existing challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 1.01 billion
Estimated Year [2024] USD 1.16 billion
Forecast Year [2030] USD 2.62 billion
CAGR (%) 14.43%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hyaluronidase Market

The Hyaluronidase Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing consumer inclination toward cosmetic and aesthetic procedures
    • Expanding production of drugs and utilization of hyaluronidase to promote drug absorption
    • Favorable regulatory approvals for hyaluronidase products
  • Market Restraints
    • Issues associated with the production and formulation of hyaluronidase solutions
  • Market Opportunities
    • Ongoing innovations and clinical trials to improve the functionality and efficiency of hyaluronidase
    • Potential for utilization of hyaluronidase in ophthalmic surgeries and efforts to raise awareness for hyaluronidase
  • Market Challenges
    • Possibility of allergic reactions and performance issues of hyaluronidase

Porter's Five Forces: A Strategic Tool for Navigating the Hyaluronidase Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hyaluronidase Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hyaluronidase Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hyaluronidase Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hyaluronidase Market

A detailed market share analysis in the Hyaluronidase Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hyaluronidase Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hyaluronidase Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hyaluronidase Market

A strategic analysis of the Hyaluronidase Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hyaluronidase Market, highlighting leading vendors and their innovative profiles. These include Alteogen Inc., Amphastar Pharmaceuticals, Inc., Argenx SE, Bausch Health Companies Inc., BBI Solutions by Novo Holdings A/S, Bioindustria L.I.M. spa, Cell Signaling Technology, Inc., Chugai Pharmaceutical Co., Ltd., CooperSurgical, Inc., Creative Enzymes, Ferro Pharma GmbH, FUJIFILM Holdings Corporation, Glentham Life Sciences Limited, GYNEMED GmbH & Co. KG by Hamilton Thorne Ltd., Halozyme Therapeutics, Inc., Innovative Research, Johnson & Johnson Services, Inc., Kitazato Corporation, Kraeber & Co GmbH, Laboratorio Innoaesthetics, S.L.U., Merck KGaA, Sanofi, Shreya Life Sciences Pvt. Ltd, STEMCELL Technologies Canada Inc., Sun Pharmaceutical Industries Limited, Sunways (India) Private Limited, Taj Pharmaceuticals Ltd., Takeda Pharmaceutical Company Limited, Wockhardt Limited, and Worthington Biochemical Corporation.

Market Segmentation & Coverage

This research report categorizes the Hyaluronidase Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Animal-Derived Hyaluronidase and Synthetic Hyaluronidase.
  • Based on Route of Administration, market is studied across Injection Route and Subcutaneous Route.
  • Based on Application, market is studied across Chemotherapy, Dermatology, Ophthalmology, and Plastic Surgery.
  • Based on End-Use, market is studied across Ambulatory Surgical Centers and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing consumer inclination toward cosmetic and aesthetic procedures
      • 5.1.1.2. Expanding production of drugs and utilization of hyaluronidase to promote drug absorption
      • 5.1.1.3. Favorable regulatory approvals for hyaluronidase products
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with the production and formulation of hyaluronidase solutions
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing innovations and clinical trials to improve the functionality and efficiency of hyaluronidase
      • 5.1.3.2. Potential for utilization of hyaluronidase in ophthalmic surgeries and efforts to raise awareness for hyaluronidase
    • 5.1.4. Challenges
      • 5.1.4.1. Possibility of allergic reactions and performance issues of hyaluronidase
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Expanding adoption of synthetic hyaluronidase owing to ongoing advancements in biotechnology and ethical considerations
    • 5.2.2. Route of Administration: Preference for injection route in clinical settings owing to its quicker systemic effects
    • 5.2.3. Application: Emerging versatile applications of hyaluronidase in dermatology for cosmetic procedures and treatment of skin conditions
    • 5.2.4. End-Use: Expansion of services and medical treatments offered by hospitals and clinics worldwide
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hyaluronidase Market, by Type

  • 6.1. Introduction
  • 6.2. Animal-Derived Hyaluronidase
  • 6.3. Synthetic Hyaluronidase

7. Hyaluronidase Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Injection Route
  • 7.3. Subcutaneous Route

8. Hyaluronidase Market, by Application

  • 8.1. Introduction
  • 8.2. Chemotherapy
  • 8.3. Dermatology
  • 8.4. Ophthalmology
  • 8.5. Plastic Surgery

9. Hyaluronidase Market, by End-Use

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Hospitals & Clinics

10. Americas Hyaluronidase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hyaluronidase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hyaluronidase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Introduction of Recombinant Human Hyaluronidase PH20 by Creative Enzymes
    • 13.3.2. Johnson & Johnson's sBLA Submission for Darzalex Faspro
    • 13.3.3. Breakthrough in Cancer Treatment with Phase 3 Trial Demonstrates Noninferiority of Subcutaneous Nivolumab in Renal Cell Carcinoma
    • 13.3.4. Approval of VYVDURA by Japan's MHLW Expands Treatment Options for gMG Patients
    • 13.3.5. Approval Expands HYQVIA Use to Maintenance Therapy for CIDP
    • 13.3.6. Revolutionary Advancement in HER2-Positive Cancer Treatment by Chugai's Launch of Phesgo in Japan
    • 13.3.7. Acumen Pharmaceuticals Partners with Halozyme to Enhance Alzheimer's Treatment Delivery
    • 13.3.8. Alteogen Inc.'s Tergase Shows Promising Results in Clinical Trials with Zero ADA Incidence
    • 13.3.9. Strategic Collaboration Between Alteogen Inc. and Sandoz AG for Licensing and Development of Subcutaneous Biosimilars
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. Merck KGaA
    • 13.4.2. Amphastar Pharmaceuticals, Inc.
    • 13.4.3. CooperSurgical, Inc.
    • 13.4.4. Halozyme Therapeutics, Inc.
    • 13.4.5. Bausch Health Companies Inc.

Companies Mentioned

  • 1. Alteogen Inc.
  • 2. Amphastar Pharmaceuticals, Inc.
  • 3. Argenx SE
  • 4. Bausch Health Companies Inc.
  • 5. BBI Solutions by Novo Holdings A/S
  • 6. Bioindustria L.I.M. spa
  • 7. Cell Signaling Technology, Inc.
  • 8. Chugai Pharmaceutical Co., Ltd.
  • 9. CooperSurgical, Inc.
  • 10. Creative Enzymes
  • 11. Ferro Pharma GmbH
  • 12. FUJIFILM Holdings Corporation
  • 13. Glentham Life Sciences Limited
  • 14. GYNEMED GmbH & Co. KG by Hamilton Thorne Ltd.
  • 15. Halozyme Therapeutics, Inc.
  • 16. Innovative Research
  • 17. Johnson & Johnson Services, Inc.
  • 18. Kitazato Corporation
  • 19. Kraeber & Co GmbH
  • 20. Laboratorio Innoaesthetics, S.L.U.
  • 21. Merck KGaA
  • 22. Sanofi
  • 23. Shreya Life Sciences Pvt. Ltd
  • 24. STEMCELL Technologies Canada Inc.
  • 25. Sun Pharmaceutical Industries Limited
  • 26. Sunways (India) Private Limited
  • 27. Taj Pharmaceuticals Ltd.
  • 28. Takeda Pharmaceutical Company Limited
  • 29. Wockhardt Limited
  • 30. Worthington Biochemical Corporation

LIST OF FIGURES

  • FIGURE 1. HYALURONIDASE MARKET RESEARCH PROCESS
  • FIGURE 2. HYALURONIDASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HYALURONIDASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HYALURONIDASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HYALURONIDASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HYALURONIDASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HYALURONIDASE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HYALURONIDASE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HYALURONIDASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HYALURONIDASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HYALURONIDASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HYALURONIDASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HYALURONIDASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HYALURONIDASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HYALURONIDASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HYALURONIDASE MARKET DYNAMICS
  • TABLE 7. GLOBAL HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HYALURONIDASE MARKET SIZE, BY ANIMAL-DERIVED HYALURONIDASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HYALURONIDASE MARKET SIZE, BY SYNTHETIC HYALURONIDASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HYALURONIDASE MARKET SIZE, BY INJECTION ROUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HYALURONIDASE MARKET SIZE, BY SUBCUTANEOUS ROUTE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HYALURONIDASE MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HYALURONIDASE MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HYALURONIDASE MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HYALURONIDASE MARKET SIZE, BY PLASTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HYALURONIDASE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HYALURONIDASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HYALURONIDASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HYALURONIDASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM HYALURONIDASE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 189. HYALURONIDASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. HYALURONIDASE MARKET, FPNV POSITIONING MATRIX, 2023